Hy­po­glycemia 'Epipen' clears Phase III, hur­tles to­ward FDA de­ci­sion

Zealand Phar­ma is one step clos­er to de­liv­er­ing a fast-act­ing in­jectable for di­a­betes pa­tients as their Hy­poPal res­cue pen has cleared every pri­ma­ry and sec­ondary end­point in a Phase III tri­al on child­hood hy­po­glycemia, con­firm­ing re­sults al­ready shown in adults and ad­vanc­ing the drug to­ward an ear­ly-2020 ap­pli­ca­tion for FDA ap­proval. The in­jec­tion, how­ev­er, was not more ef­fec­tive than ri­val Gluca­Gen – and it did make a far high­er per­cent­age of teenagers throw up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER